The supply shortage and high costs of GLP-1 weight loss drugs have created an opportunity for compounded GLP-1 treatments to ...

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.

A recent study found that over a third of websites selling compounded diabetes and weight loss medications, such as Ozempic and Wegovy, falsely claim they are FDA-approved.

Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...

Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance ...

It’s estimated 5.3 million Medicare members use the 15 drugs selected today. They account for $41 billion, or 14% of part D spending, from Nov. 1, 2023, to Oct. 31, 2024. GLP-1 drug costs over ...

A small percentage of patients taking the extraordinarily popular GLP-1 medications have experienced vision problems, but a ...

Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...